Definition: This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth character codes are applicable to all substances. Identification of the psychoactive substance should be based on as many sources of information as possible. These include self-report data, analysis of blood and other body fluids, characteristic physical and psychological symptom ...[+++]s, clinical signs and behaviour, and other evidence such as a drug being in the patient's possession or reports from informed third parties. Many drug users take more than one type of psychoactive substance. The main diagnosis should be classified, whenever possible, according to the substance or class of substances that has caused or contributed most to the presenting clinical syndrome. Other diagnoses should be coded when other psychoactive substances have been taken in intoxicating amounts (common fourth character .0) or to the extent of causing harm (common fourth character .1), dependence (common fourth character .2) or other disorders (common fourth character .3-.9). Only in cases in which patterns of psychoactive substance-taking are chaotic and indiscriminate, or in which the contributions of different psychoactive substances are inextricably mixed, should the diagnosis of disorders resulting from multiple drug use (F19.-) be used. | Modifiers The following fourth-character subdivisions are for use with categories F10-F19: Code Title .0 Acute intoxication A condition that follows the administration of a psychoactive substance resulting in disturbances in level of consciousness, cognition, perception, affect or behaviour, o ...

obligation of result [ strict liability to perform | absolute obligation ]

obligations resulting from joint ownership

legal scope of the obligations resulting from this article

obligations resulting from joint ownership

management by results [ managing for results | results-based management | results-oriented management | management by output | management by the bottom line ]

election results [ result of the polling | result of the poll | voting results ]

Definition: Personality disorder characterized by disregard for social obligations, and callous unconcern for the feelings of others. There is gross disparity between behaviour and the prevailing social norms. Behaviour is not readily modifiable by adverse experience, including punishment. There is a low tolerance to frustration and a low threshold for discharge of aggression, including violence; there is a tendency to blame others, or to offer plausible rationalizations for the behaviour bringing the patient into conflict with society. | Personality (disorder):amoral | antisocial | asocial | psychopathic | sociopathic

Definition: Mood is elevated out of keeping with the patient's circumstances and may vary from carefree joviality to almost uncontrollable excitement. Elation is accompanied by increased energy, resulting in overactivity, pressure of speech, and a decreased need for sleep. Attention cannot be sustained, and there is often marked distractibility. Self-esteem is often inflated with grandiose ideas and overconfidence. Loss of normal social inhibitions may result in behaviour that is reckless, foolhardy, or inappropriate to the circumstan ...[+++]ces, and out of character.

1. Where a participant transfers ownership of results, it shall pass on its obligations under the grant agreement regarding those results to the transferee, including the obligation to pass them on in any subsequent transfer.

Without prejudice to confidentiality obligations arising from laws or regulations in the case of mergers and acquisitions, where other participants still enjoy access rights or may still request the granting of access rights to the results to be transferred, a participant which intends to transfer the results shall give prior notice to the other participants, together with sufficient information concerning the intended new owner of the results, to permit the other participants to analyse the effect of the intended transfer on the poss ...[+++]ible exercise of their access rights.

These standards represent a generally recognised description of the detention-related obligations which must be complied with by Member States in any detention as an absolute minimum, in order to ensure compliance with European Convention on Human Rights obligations and obligations resulting from the EU Charter when applying EU law.

With reference to the side effects experienced by those taking the anti-malarial drug mefloquine (Lariam): (a) provide a detailed update on the clinical study of mefloquine (Lariam) announced by the Department of National Defence in 1997, including trial design, subject inclusion/exclusion criteria, numbers of study subjects recruited to date and participating centres; (b) have reviews been undertaken of the side effects experienced by the Australian, British and Dutch forces, if so what were the results and recommendations, and what steps have been undertaken to implement these recommendations; (c) with regard to the mefloquine (Laria ...[+++]m) used for the prophylaxis of Canadian troops deployed to Somalia, what was the nature of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (d) with regard to the mefloquine (Lariam) used for the prophylaxis of Canadian troops deployed to Somalia, what was the outcome of the Department of Health's Health Protection Branch investigations in October 1997 into the failure of the manufacturer to properly supervise and ensure compliance with the Lariam safety monitoring study and the failure of the Department of National Defence to comply with its obligations under the safety monitoring study; (e) what is the date of the insert in the mefloquine (Lariam) package used in Canada today; (f) what is the date of the product monograph for mefloquine (Lariam) used in Canada today; (g) have reviews been undertaken of the insert in the mefloquine (Lariam) package and the prescribing information used in Australia, if so what were the results and recommendations of the reviews, and what steps have been taken to implement the recommendations; (h) have reviews been undertaken ...